Background: Nivolumab has been approved for recurrent or metastatic head and neck
cancer (R/M HNC) on March 2017 in Japan. Recently, many researchers have been actively …

Background Predicting the response to treatment with nivolumab and the survival in patients
with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a …

Recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC) has a poor
prognosis. Although nivolumab is approved in Japan for treating R/MHNSCC, the response …

Although several prognostic factors in nivolumab therapy have been reported in recurrent or
metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial …

Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker
for clinical outcomes in various types of cancer, including recurrent or metastatic head and …

Background There is a need to develop biomarkers for a more efficient use of immune
checkpoint inhibitors (ICIs). Recently, it has been reported that peripheral blood …

Background There is increasing evidence that immunotherapy with nivolumab, an anti‐
programmed death 1 monoclonal antibody, is effective in the treatment of recurrent or …

Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all
patients before administering nivolumab. The aim of the present study is to clarify the …

To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1
antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated …

Purpose The importance of nivolumab for recurrent or metastatic (R/M) head and neck
squamous cell carcinoma (HNSCC) is rapidly increasing. However, prognostic factors have …